| Code | CSB-RA004847MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to HBM-1022, designed to specifically target CCR8 (C-C chemokine receptor type 8), a G protein-coupled receptor primarily expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 plays a critical role in mediating chemotaxis in response to its ligands CCL1 and CCL18, directing immune cell trafficking to sites of inflammation and within the tumor microenvironment. This receptor has emerged as a significant marker of immunosuppressive intratumoral Tregs, making it a compelling target in immuno-oncology research. Elevated CCR8 expression has been associated with various malignancies, including colorectal cancer, breast cancer, and hepatocellular carcinoma, where it contributes to immune evasion mechanisms.
HBM-1022 is a therapeutic antibody candidate that has been investigated for its potential to selectively deplete CCR8-positive Tregs in the tumor microenvironment while sparing peripheral Tregs, thereby enhancing anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating CCR8 biology, studying Treg-mediated immunosuppression, and exploring novel immunotherapeutic approaches in cancer research and inflammatory disease models.
There are currently no reviews for this product.